(Q37199327)

18 August 2017

1 reference

title

The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics (English)

1 reference

cost-effectiveness analysis

18 August 2017

0 references

1 reference

1 reference

1 reference

P Levin

1

1 reference

18 August 2017

publication date

1 July 2008

1 reference

Diabetes, Obesity and Metabolism

18 August 2017

published in

1 reference

18 August 2017

volume

10 Suppl 2

1 reference

18 August 2017

page(s)

66-75

1 reference

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00845.X

Economic costs of diabetes in the US in 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00845.X

The burden of diabetes and its complications: trends and implications for intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00845.X

Impact of the population at risk of diabetes on projections of diabetes burden in the United States: an epidemic on the way.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00845.X

Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00845.X

Changing targets in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00845.X

Multiple risk factors for cardiovascular disease and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00845.X

Role of insulin resistance and hyperglycemia in the development of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00845.X

The direct medical cost of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00845.X

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00845.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00845.X

Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00845.X

Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellit

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00845.X

An overview of insulin glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00845.X

Challenges in optimal metabolic control of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00845.X

Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00845.X

Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00845.X

Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00845.X

Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00845.X

Incremental cost savings 6 months following initiation of insulin glargine in a Medicaid fee-for-service sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00845.X

Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00845.X

Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00845.X

Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00845.X

Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00845.X

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00845.X

Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00845.X

Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00845.X

10.1111/J.1463-1326.2008.00845.X

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference